Stimcell Energetics, Inc.

Stimcell Energetics, Inc.

STME
Stimcell Energetics, Inc.US flagOther OTC
0.31
USD
- -
- -
6.64MMarket Cap
Stimcell Energetics, Inc.
STME
(Other OTC)

Recent

price

0.31

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
0.02
0.02
- -
- -
- -
0.03
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.01
-0.01
-0.01
-0.5
-1.04
-0.51
-0.55
-0.31
-0.31
-0.23
-0.17
-0.12
-0.01
-0.03
-0.03
Basic EPS, GAAP
-0.01
-0.01
- -
-0.17
-0.31
-0.35
-0.16
-0.1
-0.26
-0.14
-0.11
-0.06
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
-0.02
-0.03
-0.52
-1.56
-1.82
-2.13
-2.34
-2.24
-2.27
-2.29
-2.41
-0.96
-0.55
-0.55
Book Value per Share
0.01
- -
-0.01
-0.33
-0.68
-0.48
-0.38
-0.6
-0.43
-0.4
-0.48
-0.57
-0.08
-0.06
-0.06
Tangible Book Value per Share
2
2
2
2
2
2
3
3
4
4
4
4
11
20
20
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
-2,198.41
-5,756.09
-19,619.87
- -
- -
-1,083.6
-10,094.45
-11,074.91
-16,207.75
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
-1
-2
-1
-2
-1
-1
-1
-1
- -
- -
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-2,421.56
-5,851.51
-20,087.56
- -
- -
-1,140.32
-13,469.92
-11,498.42
-17,923.32
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-1
-2
-1
-1
-2
-2
-2
-2
-2
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
-1
-1
-1
-1
-2
-2
-2
-2
-2
-1
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Aug'25
Nov'25
May'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
- -
8
8

Working Capital

FRC

in mil. unless spec.
Aug'25
Nov'25
May'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.73%
7.06%
50.8%
Free Cash Flow
9.34%
-29.64%
-2.95%
Net Income, GAAP
22.58%
31.43%
297.44%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.01
0.01
- -
-0.01
2025
- -
-0.01
-0.01
- -
-0.03
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
StimCell Energetics, Inc. specializes in the development, manufacture, and commercialization of microcurrent-based health devices for professional and consumer use, focusing on wellness, pain management, and diagnostic applications; the company markets the eBalance Pro System for clinical settings and the eBalance Home System for at-home use, controlled by the eBalance Console that integrates multiple microcurrent algorithms. The company emphasizes its proprietary eBalance® technology as a core platform for therapeutic and non-therapeutic health products, aiming to empower individuals to manage health conditions through at-home solutions and practitioner-enabled therapies. StimCell operates primarily in the United States with corporate presence in Canada, and references indicate ongoing development and potential product iterations targeting broader consumer accessibility and streamlined, cost-effective designs. The firm was founded in the 2010s and maintains headquarters in Vancouver, British Columbia, with continued development activities and regulatory filings in North American markets. In addition to its core device systems, StimCell highlights potential ancillary offerings including diagnostic features and software-enabled workflow enhancements for both professional clinics and home users. The company’s product strategy centers on scalable microcurrent technology platforms to address diabetes-related complications, neuropathy, hypertension, kidney function concerns, and related conditions, with ongoing updates to device form factors, cost structure, and user interfaces to broaden adoption. StimCell maintains a business model that combines device sales, potential consumables or accessories, and related software services, aiming to establish a multi-channel presence across clinical and consumer healthcare environments. The company’s geographic footprint and strategic partner discussions appear oriented toward expanding distribution, clinical collaborations, and potential licensing or co-development opportunities in North American and selected international markets. StimCell’s corporate profile reflects an emphasis on R&D-driven product evolution, regulatory compliance across jurisdictions, and a pathway toward increased access to microcurrent-based health solutions for home and clinical use.

Company News

APIChatGPT
  • Stonegate Initiates Coverage on StimCell Energetics Inc. (STME)

  • StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach

  • StimCell Energetics Inc. Announces Study into eBalance(R) Device's Impact on Neuronal Mitochondrial Function

  • StimCell Energetics Inc. Successfully Uplists to OTCQB Market

  • StimCell Energetics Provides Sneak Peek at eBalance Redesign Progress and Announces Shares for Debt Transaction and the Engagement of Independent Investor Relations Consultant

  • StimCell Energetics Inc. (Formerly "Cell MedX Corp.") Announces Major Corporate Updates and Rebranding

  • Cell MedX Corp. Closes Private Placement Financing

  • Cell MedX Corp. Announces Resignation of Director

  • Cell MedX Corp. Appoints Dr. George Adams as Chairman of the Board

  • Cell MedX Corp. Announces New CEO and Directors and Debt Settlement

  • Cell MedX Corp. Announces Full Revocation of British Columbia Cease Trade Order

  • Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer